Sanofi India Limited — Others, 15-04-2025: Rumour Verification - Regulation 30(11)

Sanofi India Limited has clarified that recent news regarding a potential sale or licensing of its insulin brand, Lantus, is entirely inaccurate. The company has no intention of divesting or licensing this brand. This reassurance reinforces the company’s commitment to maintaining strong corporate governance and transparency. For investors, this announcement may strengthen confidence in the company's strategy and stability, leading to a positive outlook as it ensures continuity in its product offerings without any risk of major operational changes.